WASHINGTON (AP) -- Sanofi-Aventis investors should brace for trading volatility next week when U.S. regulators reveal their review of the company’s highly anticipated weight loss drug. The French pharmaceutical company seeks Food and Drug Administration approval of Acomplia, a drug approved in Europe for fighting obesity.
